Skip to content

Anxiety: all studies

Page 444 of 773: studies 4,431 to 4,440 of 7,721, newest first. Back to the anxiety overview

Research

Preliminary evaluation of a mindfulness intervention program in women with long COVID dysautonomia symptoms.

Brain, Behavior, & Immunity - Health March 1, 2025 Elizabeth Vandenbogaart, Matthew Figueroa, Diana Winston et al. 1 citation

The symptom burden for patients with Long COVID-associated dysautonomia is high, yet there are currently no effective treatments. Mindfulness programs reduce psychological and physical symptoms as well as inflammatory gene expression in a variety of medical conditions. The study aim was to evaluate the effect of a six-week mindfulness program in women with Long COVID dysautonomia symptoms....

Is dosage of a meditation app associated with changes in psychological distress? It depends on how you ask.

Clinical Psychological Science March 1, 2025 Simon B. Goldberg, Ashley D Kendall, Matthew J. Hirshberg et al. 15 citations

Despite growing popularity, associations between dosage and outcomes in meditation app interventions have not been established. We examined this relationship using a range of operationalizations of dosage (e.g., minutes of use, days of use, number and type of activities completed) and strategies for modeling outcomes (e.g., ordinary least squares regression, multilevel modeling, latent class...

Neural correlates of reduction in self-judgment after mindful self-compassion training: A pilot study with resting state fMRI.

Journal of Mood and Anxiety Disorders March 1, 2025 Diane Joss, Michael Datko, Charisma I. Washington et al. 5 citations

Self-judgment is a trans-diagnostic symptom among various psychological disorders, therefore can be a therapeutic target for many common psychiatric conditions. Self-judgment often arises among those who experienced childhood maltreatment, which increases the risk for developing comorbid psychiatric disorders that are resistant to traditional pharmacological and psychological interventions....

A case series of ibogaine toxicity reported to the United Kingdom National Poisons Information Service (NPIS) over a 10-year period.

Clinical Toxicology March 1, 2025 Ella P Edwards, Laurence A Gray, Muhammad E M O Elamin et al. 2 citations

Ibogaine is a psychoactive alkaloid derived from the root bark of the West African shrub Tabernanthe iboga. It is not licensed in the United Kingdom but is used by individuals to alleviate drug or alcohol use. A retrospective analysis of telephone enquiries involving ibogaine between 1 January 2012 and 31 December 2022 to the United Kingdom National Poisons Information Service was performed....

DOI: 10.1080/15563650.2024.2447500 (opens in new tab) Full text (opens in new tab) Noribogaine Cardiotoxicity Neurotoxicity Ibogaine toxicity: ibogaine +12

Clinical indicators of the suicide crisis and response to ketamine.

Journal of Affective Disorders March 1, 2025 Elizabeth D. Ballard, Lucinda Neely, Laura Waldman et al. 4 citations

This analysis sought to identify potential clinical targets for the suicide crisis. Characteristics of a useful clinical target include elevation at the time of suicide crisis and responsiveness to rapid-acting interventions. Suicidal ideation (SI), depression, and hopelessness were hypothesized to meet these criteria. Participants were 118 adults across the continuum of suicide risk, including...

Effect of continuous esketamine infusion on brain white matter microstructure in patients with major depression: A diffusion tensor imaging study.

Journal of Affective Disorders March 1, 2025 Xiang Liu, Zhipeng Wei, Lifeng Li et al. 12 citations

Esketamine has demonstrated acute antidepressant effects in patients with major depressive disorder (MDD). This study investigated whether these effects associate with reversible white matter fiber integrity recovery using diffusion imaging. Twenty patients with MDD and 20 healthy controls received 2-week esketamine treatment. Patients received 0.25 mg/kg intravenous esketamine. Emotional and...

DOI: 10.1016/j.jad.2024.12.002 (opens in new tab) Full text (opens in new tab) Major depressive disorder Mdd Antidepressants antidepressant medication Depression medication +5

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?

American Journal of Psychiatry March 1, 2025 Marjorie R. Levinstein, Reece C Budinich, Jordi Bonaventura et al. 49 citations

Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders...

DOI: 10.1176/appi.ajp.20240378 (opens in new tab) Full text (opens in new tab) Ketamine/esketamine #ketamine esketamine Ketalar Special k +4

Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.

Disease-a-month : DM March 1, 2025 Andrew M Farrar, Isabelle H Nordstrom, Kaitlyn Shelley et al. 7 citations

3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationally for its acute psychoactive effects, including euphoria and increased energy, as well as prosocial effects such as increased empathy and feelings of closeness with others. Acute adverse effects can include hyperthermia, dehydration, bruxism, and...

Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.

Journal of Parkinson's disease March 1, 2025 Vanessa Fleury, Emilie Tomkova, Sabina Catalano Chiuvé et al. 3 citations

BackgroundPsychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in patients with treatment-resistant...

DOI: 10.1177/1877718x241312604 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Parkinsons treatment Mental health outcomes Patient resilience +4

Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy

Cancer Medicine March 1, 2025 Erika Belitzky, Lis Victoria Ravani Carvalho, Melissa Taylor et al. 5 citations

ABSTRACT Purpose To evaluate the current level of evidence for the use of psychedelics for the management of cancer pain and associated psychological distress. Content Pain is a common symptom of cancer and treatment. However, there are high rates of undertreatment of cancer pain due to the complex underlying biology of the condition, and potentially due to a decrease in opioid prescribing in...